News
None of the secondary endpoints, including change in abdominal pain and nausea, and change from baseline in tissue eosinophil count and in the Eosinophilic Esophagitis Histology Scoring System and ...
Cases of eosinophilic esophagitis were systematically identified from our institution's pathology database; the criteria were the presence of epithelial proliferative changes (e.g., thickening of ...
Drops from baseline in Eosinophilic Esophagitis Histology Scoring System, Eosinophilic Esophagitis Endoscopic Reference Score, and Eosinophilic Esophagitis Activity Index were comparable; ...
Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study ...
The eosinophilic esophagitis histology scoring system (EoE-HSS) was used to assess the grade (severity) and stage (extent) of histologic features. 31 The grade and stage scores both range from 0 ...
Hosted on MSN10mon
Eupraxia reports positive data from eosinophilic esophagitis ... - MSNThe Eosinophilic Esophagitis Histology Scoring System (EoEHSS) scores, evaluating the EoE severity and extent, exhibited a mean 39% decline in Composite Stage and a 37% decline in Composite Grade ...
Diseases & Conditions Pathology of Eosinophilic Esophagitis (EoE) 2001 /viewarticle/1001600 ...
Hosted on MSN8mon
Novel Drug Improved Symptoms in Eosinophilic EsophagitisThe study enrolled 430 patients with active eosinophilic esophagitis and no response to at least 8 weeks of treatment with PPIs. Across the groups, mean age was 35-36 (6-12% were adolescents), 63 ...
HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis ...
Eupraxia Pharmaceuticals has disclosed additional positive data from its Phase Ib/IIa RESOLVE clinical trial of EP-104GI in treating eosinophilic esophagitis (EoE). The multicentre, open-label ...
HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results